ARTICLE | Company News
CoMentis, Astellas deal
October 20, 2014 7:00 AM UTC
The companies ended a 2008 deal granting Astellas exclusive, worldwide rights to develop and commercialize beta-site APP-cleaving enzyme (BACE) inhibitors for Alzheimer's disease (AD). The BACE inhib...